Search

Your search keyword '"Longinetti, Elisa"' showing total 49 results

Search Constraints

Start Over You searched for: Author "Longinetti, Elisa" Remove constraint Author: "Longinetti, Elisa"
49 results on '"Longinetti, Elisa"'

Search Results

2. COVID-19–Related Enhancement for the COMBAT-MS Study

Catalog

Books, media, physical & digital resources

3. Comparing the Safety and Effectiveness of Different Medicines to Treat Multiple Sclerosis – The COMBAT-MS Study

5. Comparing the Safety of Medicines to Treat MS during the COVID-19 Pandemic

7. Original research: Trajectories of self-reported fatigue following initiation of multiple sclerosis disease-modifying therapy.

10. Trajectories of cognitive processing speed and physical disability over 11 years following initiation of a first multiple sclerosis disease-modulating therapy

12. Trajectories of cognitive processing speed and physical disability over 11 years following initiation of a first multiple sclerosis disease-modulating therapy

14. Trajectories of cognitive processing speed and physical disability over 11 years following initiation of a first multiple sclerosis diseasemodulating therapy.

17. COVID‐19 clinical outcomes and DMT of MS patients and population‐based controls

18. COVID-19 clinical outcomes and DMT of MS patients and population-based controls

19. Mortality among family members of patients with amyotrophic lateral sclerosis : a Swedish register-based study

21. sj-docx-5-msj-10.1177_13524585211031128 – Supplemental material for Risk of depression in multiple sclerosis across disease-modifying therapies

22. sj-docx-2-msj-10.1177_13524585211031128 – Supplemental material for Risk of depression in multiple sclerosis across disease-modifying therapies

23. sj-docx-3-msj-10.1177_13524585211031128 – Supplemental material for Risk of depression in multiple sclerosis across disease-modifying therapies

24. sj-docx-1-msj-10.1177_13524585211031128 – Supplemental material for Risk of depression in multiple sclerosis across disease-modifying therapies

25. sj-docx-4-msj-10.1177_13524585211031128 – Supplemental material for Risk of depression in multiple sclerosis across disease-modifying therapies

26. Mortality among family members of patients with amyotrophic lateral sclerosis – a Swedish register-based study

30. Associations between autoimmune diseases and amyotrophic lateral sclerosis : a register-based study

31. Geographical clusters of amyotrophic lateral sclerosis and the Bradford Hill criteria.

33. ALS patients with concurrent neuroinflammatory disorders; a nationwide clinical records study.

34. Risk of depression in multiple sclerosis across disease-modifying therapies.

35. Associations between autoimmune diseases and amyotrophic lateral sclerosis: a register-based study

36. Amyotrophic lateral sclerosis and multiple sclerosis associated neuroinflammation : nationwide epidemiological studies on etiology, comorbidities, and treatment

38. The Swedish motor neuron disease quality registry

39. The Swedish motor neuron disease quality registry

41. Neurodegenerative and psychiatric diseases among families with amyotrophic lateral sclerosis

42. Physical and cognitive fitness in young adulthood and risk of amyotrophic lateral sclerosis at early age

44. Predictors of Patient-Reported Fatigue Symptom Severity in a Nationwide Multiple Sclerosis Cohort

46. Trajectories of cognitive processing speed and physical disability over 11 years following initiation of a first multiple sclerosis disease-modulating therapy.

47. Sustained Low Relapse Rate With Highly Variable B-Cell Repopulation Dynamics With Extended Rituximab Dosing Intervals in Multiple Sclerosis.

48. Mortality among family members of patients with amyotrophic lateral sclerosis - a Swedish register-based study.

49. Associations between autoimmune diseases and amyotrophic lateral sclerosis: a register-based study.